Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8491 to 8505 of 9132 results

  1. Imsamotide with etimumotide and pembrolizumab for untreated unresectable or metastatic melanoma in people 12 years and over [TSID12279]

    In development Reference number: GID-TA11882 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Oral semaglutide for managing overweight and obesity [ID6188]

    Discontinued Reference number: GID-TA11149

    Technology appraisal guidance
    Discontinued

  3. Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over [TSID11847]

    In development Reference number: GID-TA11372 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Insulin efsitora alfa for treating type 1 diabetes in people on multiple daily insulin injections [ID6498]

    In development Reference number: GID-TA11645 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Etrolizumab for previously treated moderately to severely active Crohn's disease [ID3965]

    Discontinued Reference number: GID-TA10870

    Technology appraisal guidance
    Discontinued

  6. Filgotinib for treating moderately to severely active Crohn's disease [ID6236]

    Discontinued Reference number: GID-TA11244

    Technology appraisal guidance
    Discontinued

  7. Govorestat for treating classic galactosemia in people 2 to 65 years [TSID12071]

    In development Reference number: GID-TA11634 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Diabetes - buccal insulin [ID311]

    Discontinued Reference number: GID-TAG244

    Technology appraisal guidance
    Discontinued

  9. Diabetic retinopathy - ruboxistaurin [ID382]

    Discontinued Reference number: GID-TAG386

    Technology appraisal guidance
    Discontinued

  10. Superior rectal artery embolisation for haemorrhoids

    Discontinued Reference number: GID-IPG10417

    Interventional procedures guidance
    Discontinued

  11. Glaucoma - lerdelimumab (CAT-152) [ID383]

    Discontinued Reference number: GID-TAG381

    Technology appraisal guidance
    Discontinued

  12. GID-MT557 Novii Wireless Patch System for maternal and fetal monitoring (MT509)

    Discontinued Reference number: GID-MT557

    Medical technologies guidance
    Discontinued

  13. Digital technologies for the early detection and initial diagnosis of adult hearing loss (provisional title)

    Discontinued Reference number: GID-HTG10172

    HealthTech guidance
    Discontinued

  14. Elexacaftor, tezacaftor and ivacaftor fixed dose combination therapy for treating cystic fibrosis with the F508del mutation [ID1661]

    Discontinued Reference number: GID-TA10566

    Technology appraisal guidance
    Discontinued

  15. Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

    Discontinued Reference number: GID-HST10007

    Highly specialised technologies guidance
    Discontinued